Glomerulonephritis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2025-12-08
EMA Authorised: Filspari (sparsentan) — Vifor France
The European Medicines Agency has authorised Filspari (sparsentan) for glomerulonephritis, including IgA nephropathy, with orphan designatio…